8-K - BridgeBio Oncology Therapeutics Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

On March 24, 2026, BridgeBio Oncology Therapeutics, Inc. increased its Board size to nine directors and appointed Peter Lebowitz, M.D., Ph.D. as a Class I director, effective immediately, to serve on the NCG Committee and Compensation Committee. Dr. Lebowitz, determined to be independent, received a one-time nonqualified stock option to purchase 63,350 shares at $8.72 per share.

Key Takeaways

1Board size increased to nine directors on March 24, 2026

2Peter Lebowitz, M.D., Ph.D. appointed as Class I director, term expires at 2026 annual meeting

3Dr. Lebowitz appointed to NCG Committee and Compensation Committee

4Board determined Dr. Lebowitz is independent per Nasdaq rules

5Automatic grant of stock option for 63,350 shares at $8.72 exercise price, closing price on March 24, 2026

6Compensation per amended non-employee director policy filed in 10-K on March 5, 2026

Current Report Details

Event Type

Management Change

Disclosure

Mandatory

Variant

8-K

Items Reported

5.02

Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) Director A

Management Change

$8.72director

Executive & Director Changes

Peter Lebowitz, M.D., Ph.D.

Class I Director, NCG Committee, Compensation Committee

Appointed

Effective: 2026-03-24

To fill vacancy from Board size increase to nine

Exhibits (1)

8-K